These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27897450)

  • 1. Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications.
    Invernizzi R; Travaglino E; Della Porta MG; Malcovati L; Gallì A; Bastia R; Ciola M; Ambaglio I; Boveri E; Rosti V; Cazzola M
    Leuk Lymphoma; 2017 Jul; 58(7):1711-1720. PubMed ID: 27897450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
    Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
    Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
    Tong H; Hu C; Zhuang Z; Wang L; Jin J
    Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow.
    Pecci A; Travaglino E; Klersy C; Invernizzi R
    Acta Haematol; 2003; 109(1):29-34. PubMed ID: 12486320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.
    Vasikova A; Budinska E; Belickova M; Cermak J; Bruchova H
    Neoplasma; 2009; 56(4):335-42. PubMed ID: 19469654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Bucciarelli P; Ferla V; Boiocchi L; Savi F; Moro A; Reda G; Bosari S; Cortelezzi A
    Am J Clin Pathol; 2013 Mar; 139(3):380-7. PubMed ID: 23429375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state.
    Michalopoulou S; Micheva I; Kouraklis-Symeonidis A; Kakagianni T; Symeonidis A; Zoumbos NC
    Leuk Res; 2004 Aug; 28(8):805-12. PubMed ID: 15203278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of cysteine rich 61 and vascular endothelial growth factor genes in patients with myelodysplastic syndromes and their relationship.].
    Wang ZM; Cong YQ; Ma LN; Hu XJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):745-8. PubMed ID: 20137309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
    Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
    Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of CD34(-) and CD34(+) cell apoptosis and proliferation in bone marrow of patients with MDS and their impact on survival.
    Xia B; Guo Q; Zhao DD; Zhao HF; Han XP; Wang H; Wu XX; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1392-7. PubMed ID: 23257440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expressions of survivin, Bcl-2 and VEGF in patients with myelodysplastic syndrome and their relationship].
    Sun H; Ma J; Sun L; Liu LX; Zhao LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):271-5. PubMed ID: 16638195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes.
    Vasilatou D; Papageorgiou SG; Kontsioti F; Kontos CK; Tsiotra P; Mpakou V; Pavlou MA; Economopoulou C; Dimitriadis G; Dervenoulas J; Pappa V
    Leuk Res; 2013 Mar; 37(3):251-8. PubMed ID: 23246221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin expression in acute leukemias and myelodysplastic syndromes.
    Invernizzi R; Travaglino E; Lunghi M; Klersy C; Bernasconi P; Cazzola M; Ascari E
    Leuk Lymphoma; 2004 Nov; 45(11):2229-37. PubMed ID: 15512811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
    Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
    Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z; Xie J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.